3/2/2021 7:15:34 AM
BioCryst Submits MAA To UK’s MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema
2/3/2021 7:20:34 AM
BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB
1/22/2021 7:04:42 AM
BioCryst Secures Approval Of ORLADEYO In Japan
12/22/2020 7:08:23 AM
Amended: BioCryst Expects NIAID To Discontinue Pursuit Of A COVID-19 Indication For Galidesivir
12/21/2020 7:22:16 AM
BioCryst Announces Positive Phase 1 Results With BCX9250 For Treatment Of Fibrodysplasia Ossificans Progressiva
12/16/2020 7:12:03 AM
BioCryst Says ORLADEYO Is Now Available For Shipment To Patients With A Prescription In US
12/3/2020 8:52:31 PM
BioCryst FDA Oks ORLADEYO, Oral, Once-daily Therapy To Prevent Attacks In Hereditary Angioedema Patients
11/13/2020 7:14:32 AM
BioCryst Presents New Clinical Data On Berotralstat In APeX-2 Trial